Arnab Basu

622 total citations
49 papers, 284 citations indexed

About

Arnab Basu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Arnab Basu has authored 49 papers receiving a total of 284 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 26 papers in Pulmonary and Respiratory Medicine and 23 papers in Surgery. Recurrent topics in Arnab Basu's work include Bladder and Urothelial Cancer Treatments (21 papers), Renal cell carcinoma treatment (17 papers) and Cancer Immunotherapy and Biomarkers (16 papers). Arnab Basu is often cited by papers focused on Bladder and Urothelial Cancer Treatments (21 papers), Renal cell carcinoma treatment (17 papers) and Cancer Immunotherapy and Biomarkers (16 papers). Arnab Basu collaborates with scholars based in United States, India and Denmark. Arnab Basu's co-authors include Vadim S. Koshkin, Pradnya D. Patil, Sagar Rakshit, James Stevenson, Arjun Khunger, Paul Elson, Arpita Desai, Nathan A. Pennell, Bo Hu and Monica Khunger and has published in prestigious journals such as The Lancet, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Arnab Basu

39 papers receiving 280 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Arnab Basu United States 9 165 126 87 62 58 49 284
Nayneeta Deshmukh United Kingdom 8 93 0.6× 133 1.1× 129 1.5× 94 1.5× 84 1.4× 13 319
Viktoria Stühler Germany 12 96 0.6× 157 1.2× 71 0.8× 139 2.2× 76 1.3× 34 308
Hazel Lote United Kingdom 8 116 0.7× 78 0.6× 39 0.4× 37 0.6× 22 0.4× 17 198
Miao Huang China 9 184 1.1× 159 1.3× 23 0.3× 61 1.0× 44 0.8× 17 298
Daiki Ikarashi Japan 9 159 1.0× 126 1.0× 101 1.2× 45 0.7× 39 0.7× 47 269
Rumi Higuchi Japan 11 96 0.6× 139 1.1× 41 0.5× 62 1.0× 81 1.4× 26 297
Sonal Bordia United States 6 192 1.2× 101 0.8× 98 1.1× 60 1.0× 70 1.2× 13 265
Daniel D. Kirchoff United States 12 218 1.3× 99 0.8× 71 0.8× 83 1.3× 36 0.6× 22 304
Danijel Sikic Germany 14 117 0.7× 122 1.0× 278 3.2× 134 2.2× 43 0.7× 45 427
L. Cannella Italy 9 143 0.9× 69 0.5× 77 0.9× 70 1.1× 46 0.8× 26 276

Countries citing papers authored by Arnab Basu

Since Specialization
Citations

This map shows the geographic impact of Arnab Basu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arnab Basu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arnab Basu more than expected).

Fields of papers citing papers by Arnab Basu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arnab Basu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arnab Basu. The network helps show where Arnab Basu may publish in the future.

Co-authorship network of co-authors of Arnab Basu

This figure shows the co-authorship network connecting the top 25 collaborators of Arnab Basu. A scholar is included among the top collaborators of Arnab Basu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arnab Basu. Arnab Basu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Brown, Jason R., Tolulope Adeyelu, Andrew Elliott, et al.. (2025). Real-world analysis of 2IR immune response score in urothelial carcinoma (UC).. Journal of Clinical Oncology. 43(5_suppl). 739–739. 1 indexed citations
2.
Bibi, Maryam, Kelly Stratton, Michael S. Cookson, et al.. (2025). The prognostic role of circulating tumor DNA (ctDNA) clearance as a biomarker in localized and metastatic renal cell carcinoma (RCC): A single-center experience.. Journal of Clinical Oncology. 43(5_suppl). 570–570.
3.
Basu, Arnab, et al.. (2025). Future Directions for Circulating Tumor DNA Studies in Renal Cell Carcinoma. European Urology Focus. 11(3). 429–431.
4.
Ismail, Ahmed, Chinmay Jani, M. Midhun, et al.. (2025). HER2 alterations across solid tumors: implications for comprehensive testing. The Oncologist. 30(9).
5.
Basu, Arnab, Meenakshi Malhotra, Adam C. ElNaggar, et al.. (2024). Longitudinal Testing of Circulating Tumor DNA in Patients With Metastatic Renal Cell Carcinoma. JCO Precision Oncology. 8(8). e2400667–e2400667. 4 indexed citations
6.
Ornstein, Moshe Chaim, Wei Wei, C. Marcela Díaz‐Montero, et al.. (2024). Phase II Trial of Intermittent Therapy in Patients with Metastatic Renal Cell Carcinoma Treated with Front-line Ipilimumab and Nivolumab. Clinical Genitourinary Cancer. 22(6). 102181–102181.
7.
Alhalabi, Omar, Dimitra Rafailia Bakaloudi, Amanda Nizam, et al.. (2024). Impact of squamous histology on outcomes with enfortumab vedotin in patients with advanced urothelial carcinoma: Analysis of the UNITE study.. Journal of Clinical Oncology. 42(4_suppl). 651–651. 1 indexed citations
8.
Jiang, Changying, Omar Alhalabi, Amanda Nizam, et al.. (2024). 8P Factors associated with primary progression in patients with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin (EV): Analysis of the UNITE study. ESMO Open. 9. 102263–102263. 1 indexed citations
9.
Choueiri, Toni K., Laurence Albigès, Philippe Barthélémy, et al.. (2024). Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study. The Lancet. 404(10460). 1309–1320. 32 indexed citations
10.
Laliotis, George, Shivaram Cumarasamy, Samuel Rivero-Hinojosa, et al.. (2024). Performance of a tumor-informed molecular residual disease (MRD) assay in resected bladder cancer with mixed or pure variant histology: Analysis of a real-world multicenter cohort.. Journal of Clinical Oncology. 42(4_suppl). 649–649. 1 indexed citations
11.
Barata, Pedro C., Shuchi Gulati, Andrew Elliott, et al.. (2024). Renal cell carcinoma histologic subtypes exhibit distinct transcriptional profiles. Journal of Clinical Investigation. 134(11). 8 indexed citations
12.
Patel, Shefali, et al.. (2024). High Sensitivity Circulating Tumor-DNA Assays in Renal Cell Carcinoma–Are we there yet?. Clinical Genitourinary Cancer. 22(6). 102235–102235.
13.
Caine, S. Barak, Jang‐Yang Chang, Arnab Basu, et al.. (2023). Sprague Dawley rats from different vendors vary in the modulation of prepulse inhibition of startle (PPI) by dopamine, acetylcholine, and glutamate drugs. Psychopharmacology. 240(9). 2005–2012. 2 indexed citations
14.
Basu, Arnab, et al.. (2023). Mechanisms of tyrosine kinase inhibitor resistance in renal cell carcinoma. Cancer Drug Resistance. 6(4). 858–73. 15 indexed citations
15.
Nizam, Amanda, Li Zhang, Omar Alhalabi, et al.. (2023). 2394P Biomarkers of treatment (Tx)-related toxicity in advanced urothelial carcinoma (aUC) pts treated with enfortumab vedotin (EV): Analysis of UNITE study. Annals of Oncology. 34. S1219–S1219. 3 indexed citations
16.
Basu, Arnab, et al.. (2022). Understanding the Uptake and Challenges of Genetic Testing Guidelines for Prostate Cancer Patients. Cancer Treatment and Research Communications. 32. 100588–100588. 10 indexed citations
17.
Koshkin, Vadim S., Yi Sun, Christopher Su, et al.. (2020). 771P Efficacy of enfortumab vedotin in populations of interest among patients with advanced urothelial cancer. Annals of Oncology. 31. S594–S594. 2 indexed citations
18.
Barata, Pedro C., Arpita Desai, Vadim S. Koshkin, et al.. (2020). Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort. Frontiers in Oncology. 10. 581189–581189. 12 indexed citations
19.
Maiti, Abhishek, et al.. (2016). Type 4 Hiatal Hernia. The American Journal of the Medical Sciences. 351(3). e5–e5. 1 indexed citations
20.
Basu, Arnab, et al.. (1990). Trichouria Due to Benign Retrovesical Teratoma. British Journal of Urology. 65(6). 659–660.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nayneeta Deshmukh Breakdown of academic impact, for papers by Viktoria Stühler Breakdown of academic impact, for papers by Hazel Lote Breakdown of academic impact, for papers by Miao Huang Breakdown of academic impact, for papers by Daiki Ikarashi Breakdown of academic impact, for papers by Rumi Higuchi Breakdown of academic impact, for papers by Sonal Bordia Breakdown of academic impact, for papers by Daniel D. Kirchoff Breakdown of academic impact, for papers by Danijel Sikic Breakdown of academic impact, for papers by L. Cannella
Rankless by CCL
2026